372 related articles for article (PubMed ID: 21586680)
1. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
[TBL] [Abstract][Full Text] [Related]
2. Incidence of nephrogenic systemic fibrosis at two large medical centers.
Prince MR; Zhang H; Morris M; MacGregor JL; Grossman ME; Silberzweig J; DeLapaz RL; Lee HJ; Magro CM; Valeri AM
Radiology; 2008 Sep; 248(3):807-16. PubMed ID: 18710976
[TBL] [Abstract][Full Text] [Related]
3. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
[TBL] [Abstract][Full Text] [Related]
4. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities.
Wertman R; Altun E; Martin DR; Mitchell DG; Leyendecker JR; O'Malley RB; Parsons DJ; Fuller ER; Semelka RC
Radiology; 2008 Sep; 248(3):799-806. PubMed ID: 18632533
[TBL] [Abstract][Full Text] [Related]
5. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients.
Abujudeh HH; Rolls H; Kaewlai R; Agarwal S; Gebreananya ZA; Saini S; Schaefer PW; Kay J
J Magn Reson Imaging; 2009 Dec; 30(6):1335-40. PubMed ID: 19937927
[TBL] [Abstract][Full Text] [Related]
6. Incidence of nephrogenic systemic fibrosis at Chinese PLA General Hospital.
Zou Z; Ma L; Li H
J Magn Reson Imaging; 2009 Dec; 30(6):1309-12. PubMed ID: 19937931
[TBL] [Abstract][Full Text] [Related]
7. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.
Perez-Rodriguez J; Lai S; Ehst BD; Fine DM; Bluemke DA
Radiology; 2009 Feb; 250(2):371-7. PubMed ID: 19188312
[TBL] [Abstract][Full Text] [Related]
8. Nephrogenic systemic fibrosis: risk factors and incidence estimation.
Sadowski EA; Bennett LK; Chan MR; Wentland AL; Garrett AL; Garrett RW; Djamali A
Radiology; 2007 Apr; 243(1):148-57. PubMed ID: 17267695
[TBL] [Abstract][Full Text] [Related]
9. Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden.
Alhadad A; Sterner G; Svensson Å; Alhadad H; Leander P
Scand J Urol Nephrol; 2012 Feb; 46(1):48-53. PubMed ID: 22008005
[TBL] [Abstract][Full Text] [Related]
10. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?
Nandwana SB; Moreno CC; Osipow MT; Sekhar A; Cox KL
Radiology; 2015 Sep; 276(3):741-7. PubMed ID: 25875973
[TBL] [Abstract][Full Text] [Related]
11. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
12. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.
Abujudeh HH; Kaewlai R; Kagan A; Chibnik LB; Nazarian RM; High WA; Kay J
Radiology; 2009 Oct; 253(1):81-9. PubMed ID: 19709997
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for NSF: a literature review.
Prince MR; Zhang HL; Roditi GH; Leiner T; Kucharczyk W
J Magn Reson Imaging; 2009 Dec; 30(6):1298-308. PubMed ID: 19937930
[TBL] [Abstract][Full Text] [Related]
14. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study.
Amet S; Launay-Vacher V; Clément O; Frances C; Tricotel A; Stengel B; Gauvrit JY; Grenier N; Reinhardt G; Janus N; Choukroun G; Laville M; Deray G
Invest Radiol; 2014 Feb; 49(2):109-15. PubMed ID: 24169070
[TBL] [Abstract][Full Text] [Related]
15. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis.
Becker S; Walter S; Witzke O; Kreuter A; Kribben A; Mitchell A
Nephron Clin Pract; 2012; 121(1-2):c91-4. PubMed ID: 23182840
[TBL] [Abstract][Full Text] [Related]
16. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
[TBL] [Abstract][Full Text] [Related]
17. Nephrogenic systemic fibrosis: center case review.
Lauenstein TC; Salman K; Morreira R; Tata S; Tudorascu D; Baramidze G; Singh-Parker S; Martin DR
J Magn Reson Imaging; 2007 Nov; 26(5):1198-203. PubMed ID: 17969162
[TBL] [Abstract][Full Text] [Related]
18. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
Prince MR; Zhang HL; Prowda JC; Grossman ME; Silvers DN
Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
[TBL] [Abstract][Full Text] [Related]
19. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine.
Hope TA; Herfkens RJ; Denianke KS; LeBoit PE; Hung YY; Weil E
Invest Radiol; 2009 Mar; 44(3):135-9. PubMed ID: 19151610
[TBL] [Abstract][Full Text] [Related]
20. Risk of nephrogenic systemic fibrosis in liver transplantation patients.
Chow DS; Bahrami S; Raman SS; Rotchel S; Sayre JW; Busuttil RW; Lu DS
AJR Am J Roentgenol; 2011 Sep; 197(3):658-62. PubMed ID: 21862808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
